OncLive® On Air

In this podcast, experts Shazia Nakhoda, MD; Shruti Gupta, MD, MPH; and Anitha Varghese, MSN, APRN, AGPCNP-C, discuss prevention and treatment of acute kidney injury in patients receiving high-dose methotrexate.

From Discovery to Delivery: Charting Progress in Gynecologic Oncology, hosted by Ursula A. Matulonis, MD, brings expert insights into the most recent breakthroughs, evolving standards, and emerging therapies across gynecologic cancers. Dr Matulonis is chief of the Division of Gynecologic Oncology and the Brock-Wilcon Family Chair at the Dana-Farber Cancer Institute, as well as a professor of medicine at Harvard Medical School, both in Boston, Massachusetts.In this episode, Dr Matulonis sat down with guest Rebecca Porter, MD, PhD. Dr Porter is a physician at Dana-Farber Cancer Institute and an assistant professor of medicine at Harvard Medical School.Drs Matulonis and Porter discussed the evolving role of immunotherapy in gynecologic cancer management, focusing on recent clinical breakthroughs and future directions. They noted that although high-grade serous ovarian cancer has historically been refractory to immunotherapy, the phase 3 KEYNOTE-B96 trial (NCT05116189) demonstrated an efficacy benefit with the addition of pembrolizumab to weekly paclitaxel for patients with platinum-resistant disease. In particular, improvements in overall survival were noted in the PD-L1–positive patient population. Dr Porter attributed this success to the metronomic weekly dosing of paclitaxel, which may increase neoantigen levels and favorably alter the tumor microenvironment (TME).Moreover, the experts highlighted how immunotherapy has already become the standard of care for patients with mismatch repair–deficient advanced or recurrent endometrial cancer. However, they explained that for the mismatch repair–proficient population, this benefit is less clear and appears most significant in patients with measurable disease or specific molecular subtypes. They added that although circulating tumor DNA (ctDNA) assay results correlate with treatment outcomes, ctDNA is currently not an actionable biomarker for determining treatment duration or selection.Lastly, Drs Matulonis and Porter reported that the field of gynecologic oncology is shifting toward combination therapies and novel platforms beyond standard checkpoint inhibitors. Treatment advances include bispecific and trispecific antibodies that engage multiple cell types or signals; as well as adoptive cellular therapies, such as CAR T-cell and CAR natural killer–cell therapies. Ultimately, the experts concluded that the goal of managing challenging-to-treat diseases like ovarian cancer is to use combinatorial approaches—incorporating vaccines, anti-angiogenic therapies, and chemotherapy—to overcome the immunosuppressive nature of the TME.

In this podcast, experts Tiffany A. Traina, MD, FASCO; Nour Abuhadra, MD; Joshua Z. Drago, MD, MS; Ruth O’Regan, MD; Vered Stearns, MD, FASCO; Neil Vasan, MD, PhD; and Anna Weiss, MD, discuss the evolving treatment landscape across breast cancer subtypes and lines of care. Gamified case-based discussion will focus on integrating the latest practice-changing data into clinical practice to optimize care for patients with breast cancer.

In this podcast, experts William J. Gradishar, MD, FASCO, FACP; Stephanie L. Graff, MD, FACP, FASCO; and Cynthia X. Ma, MD, PhD; discuss current and emerging therapeutic options, including next-generation endocrine therapies, to target the estrogen receptor signaling pathway for the treatment of hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (MBC).

In this podcast, experts Charles M. Rudin, MD, PhD; Anne Chiang, MD, PhD, FASCO; and Jacob M. Sands, MD; discuss immune checkpoint inhibitor–based strategies in limited-stage (LS) and extensive-stage (ES) small cell lung cancer (SCLC), practical considerations for integrating novel agents such as tarlatamab and lurbinectedin, and the emerging role of antibody-drug conjugates in the treatment of ES-SCLC.

In this podcast, experts Shubham Pant, MD, MBBS; Alison Schram, MD; and Helena Yu, MD, discuss the role of RAS alterations in solid tumors, including gastrointestinal, gynecologic, and thoracic malignancies.

In today’s episode, the discussion features Guillermo Garcia-Manero, MD, who reviewed the clinical rationale for targeting BCL-2 in higher-risk myelodysplastic syndrome (MDS) and outlined the phase 3 GLORA-4 trial (NCT06641414) evaluating lisaftoclax (APG-2575) plus azacitidine (Vidaza) in this population. Dr Garcia-Manero is the chair ad interim in the Department of Leukemia in the Division of Cancer Medicine, as well as leader of the MDS/AML Moon Shot Program, at The University of Texas MD Anderson Cancer Center in Houston.In the exclusive interview, Dr Garcia-Manero contextualized lisaftoclax as a next-generation BCL-2 inhibitor being advanced as a hypomethylating agent (HMA) partner strategy intended to improve on outcomes historically achieved with azacitidine alone in higher-risk MDS. He emphasized that GLORA-4 is designed as a registrational, randomized trial to rigorously assess whether adding BCL-2 inhibition to standard HMAs can meaningfully deepen responses and translate into clinically relevant benefit. He also characterized the regimen’s tolerability profile in a population that often requires careful supportive care and dose management.

In this podcast, experts Erika P. Hamilton, MD; Giuseppe Curigliano, MD, PhD; VK Gadi, MD, PhD; Jason Aboudi Mouabbi, MD, discuss frontline, second-line, and antibody-drug conjugate therapies for the treatment of HR-positive, HER2-negative metastatic breast cancer.

In this podcast, experts Tiffany A. Traina, MD, FASCO, Kevin Kalinsky, MD, MS, FASCO, Mark E. Robson, MD, FASCO, and Rebecca Shatsky, MD discuss data for CDK4-6 inhibitors, PARP inhibitors, and immune checkpoint inhibitors in the management of early-stage hormone receptor-positive, HER-2-negative breast cancer.

In this podcast, experts Scott T. Tagawa, MD, MS, FASCO, FACP; Himisha Beltran, MD; and Neeta Pandit-Taskar, MD, MBA, discuss the latest evidence on PSMA PET and RLT, including combination strategies, selection, sequencing, toxicity monitoring, and operations, with careful attention to access and equity.